Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2002

View Archived Issues

Antalarmin, a CRF1 antagonist, for the therapy of anxiety

SN-38 induces cell cycle arrest and apoptosis in human testicular cancer cells

Structure of FAAH elucidated

Arzoxifene and LG-100268 effective alone and in combination in a rat breast cancer model

Shigella vaccine is safe and immunogenic in phase I trial

Alliance and Mixture Sciences enter technology license agreement

Statistically significant preliminary results in Visudyne study in minimally classic wet AMD

Fujisawa expands topical Atrisone collaboration with Atrix

VaxGen and Kaketsuken sign agreement for smallpox vaccine development

Efficacy of alicaforsen reported in patients with active Crohn's disease

Antiarrhythmic action of a novel arylpiperazine RSD-992 shown in rats and guinea pigs

CP-461 well tolerated in a phase I trial in patients with advanced cancer

Phase II asthma trial of interferon gamma-1b completes randomization

Initial milestone achieved in Applied Molecular Evolution/Chiron collaboration

AVI BioPharma and International Therapeutics to develop NeuGene compounds for HIV

Drug pipeline for allergic rhinitis

BLA amendment for Xolair includes new data

Phase II trial of VX-148 in psoriasis patients commences in Iceland

Novel inhibitors of cytokine production covered by Boehringer Ingelheim patent

Aventis researchers design novel agents for in vitro and in vivo nucleic acid delivery

Decalactones of fungal origin reported to exhibit antitumor and antiinfective activity

New antithrombotic 5-thio-beta-D-xylopyranose derivatives under study at Fournier

Piperidine-based motilin agonists described by Solvay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...